Sanofi SA logo

SAN - Sanofi SA Share Price

€81.63 0.1  0.1%

Last Trade - 18/01/21

Large Cap
Market Cap £90.86bn
Enterprise Value £99.01bn
Revenue £33.45bn
Position in Universe 8th / 846
Unlock SAN Revenue
Relative Strength (%)
1m +1.30%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -14.9%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
31,999 34,861 34,696 36,221 35,677 37,631 36,797 38,211 +3.3%
-8.9 +27.9 -11.4 -6.4 +27.3 +13.9 +9.29 +8.89
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 30 September 2020, SanofiSA revenues increased 3% to EUR19.2B. Net income beforeextraordinary items increased 21% to EUR3.64B. Revenuesreflect Pharmaceuticals segment increase from EUR129M toEUR11.13B, Vaccines segment increase from EUR615M toEUR2.47B, United States segment increase of 12% to EUR6.95B, Europe segment increase of 7% to EUR4.65B.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for SAN
Graphical History


SAN Revenue Unlock SAN Revenue

Net Income

SAN Net Income Unlock SAN Revenue

Normalised EPS

SAN Normalised EPS Unlock SAN Revenue

PE Ratio Range

SAN PE Ratio Range Unlock SAN Revenue

Dividend Yield Range

SAN Dividend Yield Range Unlock SAN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
SAN EPS Forecasts Unlock SAN Revenue
Profile Summary

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme. It partners with Alnylam Pharmaceuticals.

Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated May 11, 1994
Public Since July 1, 2002
No. of Shareholders: n/a
No. of Employees: 100,409
SAN Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for SAN
Upcoming Events for SAN
Friday 5th February, 2021
Q4 2020 Sanofi SA Earnings Release
Friday 5th February, 2021
Q4 2020 Sanofi SA Earnings Call
Wednesday 28th April, 2021
Q1 2021 Sanofi SA Earnings Release
Wednesday 28th April, 2021
Q1 2021 Sanofi SA Earnings Call
Friday 30th April, 2021
Sanofi SA Annual Shareholders Meeting
Frequently Asked Questions for Sanofi SA
What is the Sanofi SA share price?

As of 18/01/21, shares in Sanofi SA are trading at €81.63, giving the company a market capitalisation of £90.86bn. This share price information is delayed by 15 minutes.

How has the Sanofi SA share price performed this year?

Shares in Sanofi SA are currently trading at €81.63 and the price has moved by -11% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Sanofi SA price has moved by -7.03% over the past year.

What are the analyst and broker recommendations for Sanofi SA?

Of the analysts with advisory recommendations for Sanofi SA, there are there are currently 8 "buy" , 9 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Sanofi SA is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Sanofi SA next release its financial results?

Sanofi SA is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Sanofi SA dividend yield?

The Sanofi SA dividend yield is 3.86% based on the trailing twelve month period.

Does Sanofi SA pay a dividend?

Last year, Sanofi SA paid a total dividend of 3.15, and it currently has a trailing dividend yield of 3.86%. Looking ahead, Sanofi SA has not announced an ex-dividend date yet.

When does Sanofi SA next pay dividends?

Sanofi SA has yet to annouce their ex-dividend date. The historic dividend yield on Sanofi SA shares is currently 3.86%.

How do I buy Sanofi SA shares?

To buy shares in Sanofi SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Sanofi SA?

Shares in Sanofi SA are currently trading at €81.63, giving the company a market capitalisation of £90.86bn.

Where are Sanofi SA shares listed? Where are Sanofi SA shares listed?

Here are the trading details for Sanofi SA:

Country of listing: France
Exchange: PAR
Ticker Symbol: SAN
What kind of share is Sanofi SA?

Based on an overall assessment of its quality, value and momentum, Sanofi SA is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Sanofi SA share price forecast 2021?

Shares in Sanofi SA are currently priced at €81.63. At that level they are trading at 20.92% discount to the analyst consensus target price of 0.00.

Analysts covering Sanofi SA currently have a consensus Earnings Per Share (EPS) forecast of 5.784 for the next financial year.

How can I tell whether the Sanofi SA share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sanofi SA. Over the past six months, the relative strength of its shares against the market has been -19.45%. At the current price of €81.63, shares in Sanofi SA are trading at -5.47% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Sanofi SA PE Ratio?

The Sanofi SA PE ratio based on its reported earnings over the past 12 months is 15.41. The shares are currently trading at €81.63.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Sanofi SA?

Sanofi SA's management team is headed by:

Olivier Charmeil - EVP
Philippe Luscan - EVP
Claudie Haignere - IND
Serge Weinberg - CHM
Laurent Attal - DRC
Karen Linehan - EVP
David Loew - EVP
Patrick Kron - IND
Bernard Charles - IND
Alan Main - EVP
Jean-Baptiste Chasseloup de Chatillon - CFO
John Reed - EVP
Christophe Babule - DRC
Caroline Luscombe - EVP
Paul Hudson - CEO
Who are the major shareholders of Sanofi SA?

Here are the top five shareholders of Sanofi SA based on the size of their shareholding:

L'Oreal SA Corporation
Percentage owned: 9.38% (118.1m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 5.87% (73.9m shares)
Caisse des Dépôts et Consignations Investment Advisor
Percentage owned: 4.74% (59.6m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 2.4% (30.2m shares)
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund
Percentage owned: 2.09% (26.4m shares)
Similar to SAN
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.